Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
2seventy bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G/A STATE STREET CORP reports a 2.1% stake in EXIT FILING 2SEVENTY BIO INC
08/24/2023 4 Leschly Nick (President and CEO) has filed a Form 4 on 2seventy bio, Inc.
Txns: Sold 9,312 shares @ $5.4865, valued at $51.1k
08/24/2023 4 Gregory Philip D (Chief Scientific Officer) has filed a Form 4 on 2seventy bio, Inc.
Txns: Sold 6,159 shares @ $5.4865, valued at $33.8k
08/24/2023 4 Baird William D III (CFO) has filed a Form 4 on 2seventy bio, Inc.
Txns: Sold 7,031 shares @ $5.4865, valued at $38.6k
08/16/2023 4 Kynam Global Healthcare Master Fund, LP (10% Owner) has filed a Form 4 on 2seventy bio, Inc.
Txns: Bought 179,000 shares @ $5.94, valued at $1.1M
Bought 50,000 shares @ $5.8, valued at $290k
Bought 100,000 shares @ $5.85, valued at $585k
Bought 100,000 shares @ $5.96, valued at $596k
Bought 86,414 shares @ $5.96, valued at $515k
Bought 86,414 shares @ $5.96, valued at $515k
08/16/2023 3 Kynam Global Healthcare Master Fund, LP (10% Owner) has filed a Form 3 on 2seventy bio, Inc.
08/14/2023 4 Kynam Capital Management, LP (10% Owner) has filed a Form 4 on 2seventy bio, Inc.
Txns: Bought 179,000 shares @ $5.94, valued at $1.1M
Bought 50,000 shares @ $5.8, valued at $290k
Bought 100,000 shares @ $5.85, valued at $585k
Bought 100,000 shares @ $5.96, valued at $596k
Bought 86,414 shares @ $5.96, valued at $515k
Bought 86,414 shares @ $5.96, valued at $515k
08/14/2023 3 Kynam Capital Management, LP (10% Owner) has filed a Form 3 on 2seventy bio, Inc.
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress Abecma generated $115 million U.S. commercial revenue in 2Q 2023, supporting lower end of U.S. revenue guidance of $470-570 million"
08/07/2023 4 Leschly Nick (President and CEO) has filed a Form 4 on 2seventy bio, Inc.
Txns: Sold 9,060 shares @ $6.1257, valued at $55.5k
08/07/2023 4 Gregory Philip D (Chief Scientific Officer) has filed a Form 4 on 2seventy bio, Inc.
Txns: Sold 3,966 shares @ $6.1257, valued at $24.3k
08/07/2023 4 Baird William D III (CFO) has filed a Form 4 on 2seventy bio, Inc.
Txns: Sold 6,906 shares @ $6.1257, valued at $42.3k
07/27/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure  Interactive Data
06/15/2023 4 Ibrahim Ramy (Director) has filed a Form 4 on 2seventy bio, Inc.
Txns: Granted 8,400 shares @ $0
Granted 16,900 options to buy @ $11.81, valued at $199.6k
06/15/2023 4 Torres Denice (Director) has filed a Form 4 on 2seventy bio, Inc.
Txns: Granted 8,400 shares @ $0
Granted 16,900 options to buy @ $11.81, valued at $199.6k
06/15/2023 4 Maus Marcela V. (Director) has filed a Form 4 on 2seventy bio, Inc.
Txns: Granted 8,400 shares @ $0
Granted 16,900 options to buy @ $11.81, valued at $199.6k
06/15/2023 4 Glickman Sarah JS (Director) has filed a Form 4 on 2seventy bio, Inc.
Txns: Granted 8,400 shares @ $0
Granted 16,900 options to buy @ $11.81, valued at $199.6k
06/15/2023 4 LYNCH DANIEL (Director) has filed a Form 4 on 2seventy bio, Inc.
Txns: Granted 8,400 shares @ $0
Granted 16,900 options to buy @ $11.81, valued at $199.6k
06/15/2023 4 Wei Lin (Director) has filed a Form 4 on 2seventy bio, Inc.
Txns: Granted 4,200 shares @ $0
Granted 8,450 options to buy @ $11.81, valued at $99.8k
05/19/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2 3 4 8",
"Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed"
05/17/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio bbT369, a dual-targeted and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models"
05/01/2023 SC 13G CITADEL ADVISORS LLC reports a 5.2% stake in 2seventy bio, Inc.
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/01/2023 8-K Other Events  Interactive Data
Docs: "2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program 2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023"
04/27/2023 8-K Quarterly results
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/17/2023 8-K Quarterly results
03/17/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress Abecma generated $94M U.S. commercial revenue in 4Q 2022, $297M in FY 2022&#59; anticipate $470-$570M U.S. revenue in 2023"
03/09/2023 4 Wei Lin (Director) has filed a Form 4 on 2seventy bio, Inc.
Txns: Granted 16,600 shares @ $0
Granted 33,400 options to buy @ $10.91, valued at $364.4k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy